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Dear editor
Elizabethkingia meningoseptica is ubiquitous in soil and water as well as in 
hospital environments1,2,3. Thus, nosocomial outbreaks of E. meningoseptica can 
result from exposure to contaminated water sources or medical devices2. Due to 
the therapeutic challenge resulting from multi-drug resistance, recognition and 
treatment of E. meningoseptica is of paramount importance for clinicians2,3. We 
report a case of bacteremia due to a multi-drug resistant E. meningoseptica in a 
patient who required assisted ventilation due to respiratory failure.
A 62-year-old male, who had had a history of oral cancer with operation and 
concurrent chemoradiotherapy, diabetes mellitus, bilateral vocal palsy, upper airway 
obstruction followed by tracheostomy and chronic obstructive pulmonary disease, 
developed cough with shortness of breath prior to admission. He was admitted 
to the intensive care ward because of impending respiratory failure. Ventilation 
support with Evita 4 (Dräger, Lubeck, Germany) was used, and he was transferred 
to the respiratory care center (RCC) for weaning twenty-one days later, because 
of fluctuations in his respiratory condition associated with underlying pulmonary 
problems. A new fever episode appeared on the 11th day after transfer to RCC 
(Figure 1). The lungs showed crackles on the right side. Laboratory analyses 
revealed a white blood cell count of 10,800 cells/ mm3. The serum creatinine level 
was 2.3 mg/dL. The chest X-ray showed a new pneumonic patch over the left lower 
lobe. E. meningoseptica (2/2 sets) was identified by using matrix-assisted laser 
desorption ionization-time of flight mass spectrometry (bioMerieux, Hazlewood, 
Mo.). An antimicrobial drug susceptibility test4 was conducted for E. meningoseptica 
by using the bioMérieux VITEK 2 system (bioMerieux, Hazlewood, MO.), and the 
minimum inhibitory concentration (MIC) was measured for each of the following 
antimicrobial drugs: piperacillin-tazobactam, cefotaxime, flomoxef, ceftazidime, 
cefepime, cefoperazone, amikacin, gentamicin, ciprofloxacin, levofloxacin, 
imipenem-cilastatin, meropenem, trimethoprim-sulfamethoxazole, doxycycline and 
colistin (Table 1). In addition, MIC results determined by the Epsilometer test (AB 
Biodisk, Sweden system) were: ciprofloxacin ≧4 μg/mL; levofloxacin ≧8 μg/mL; 
imipenem-cilastatin ≧16 μg/mL; meropenem ≧16 μg/mL; trimethoprim-
sulfamethoxazole ≧4/ 76 μg/mL; and vancomycin ≧16 μg/mL. The patient 
received a combination of intravenous ciprofloxacin (200 mg every 12 hours) and 
imipenem-cilastatin (250 mg every 6 hours). His condition stabilized gradually and 
the follow-up chest X-ray showed improvement. Due to difficulty in weaning, he 
was transferred to a respiratory care ward after 42 days of hospitalization at RCC. 
No outbreak of E. meningoseptica infection was reported during the period of 
hospitalization at RCC. The follow-up of microbiological analyses for this patient 
did not show E. meningoseptica infection.
The appropriate choice of antibiotics for treatment of E. meningoseptica infection 
is difficult because optimal antimicrobial guidelines remain to be established2,3. 
Herein, the antimicrobial drug susceptibility test of this E. meningoseptica 
showed resistance to all the antibiotics, including trimethoprim-sulfamethoxazole 
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Figure 1 - Timeline of the Elizabethkingia meningoseptica infection, serial chest X-ray images and serial antibiotics history
Green Line: medical intensive care unit; Black Line: respiratory care center; Blue Line: respiratory care ward; Brown Line: 
antibiotics regimen for Elizabethkingia meningoseptica; Brown dot line: history of antibiotics usage.
Notes: 1Antibiotics history: flomoxef 1,000 mg ib q12h (MICU Day1 - MICU Day 6) for empirical therapy; ciprofloxacin 200 ib q12h 
(MICU Day 6-MICU Day 8) for coverage of P. aeruginosa, and stop ciprofloxacin due to no significant evidence of pulmonary infection 
by P. aeruginosa; no antibiotics ( MICU Day 8- RCC Day 11); piperacilin 3,000 mg ib q6h (RCC Day 11- RCC Day 14) empirically 
for new fever episode. 2weaning index: synchronized intermittent mode was 6/minute with pressure support 16 cmH2O, FiO2 was 
30 %, positive end-expiratory pressure was 5 cmH2O, rapid shallow breathing index was 96. 3weaning index: bi-level positive airway 
pressure mode assisted with pressure control mode 22/ minute, FiO2 was 30%, positive end-expiratory pressure was 8 cmH2O, 
tidal volume was 455 cm H2o, ventilation rate was 16/ minute, total mechanical volume was 10.9 L /minute. 4Antibiotics history: No 
prescription of antibiotics (RCC Day 28- RCC Day 42).
Abbreviation: ib: in bag drip; M, male; MICU: medical intensive care unit; RCC: respiratory care center; s/p, status of post; WBC: 
white cell count.
Table 1 - Susceptibilities of this isolate to the antimicrobial agents
E-test 3 VITEK 24 MIC interpretation criteria (μg/mL)
Antimicrobial agent 1 This isolate S I R
Amikacin ≧64 ≤ 16 32 ≥ 64
Cefepime ≧32 ≤ 8 16 ≥ 32
Cefoperazone ≧64 ≤ 16 32 ≥ 64
Cefotaxime ≧32 ≤ 8 16-32 ≥ 32
Flomoxef ≧64 (pending)
Ceftazidime ≧32 ≤ 8 16 ≥ 32
Ciprofloxacin ≧4 ≧4 ≤ 1 2 ≥ 4
Colistin ≧16 ≤ 2 4 ≥ 8
Doxycycline ≧16 ≤ 4 8 ≥ 16
Gentamicin ≧16 ≤ 4 8 ≥ 16
Imipenem ≧16 ≧16 ≤ 4 8 ≥ 16
Levofloxacin ≧8 ≧8 ≤ 2 4 ≥ 8
Meropenem ≧16 ≤ 4 8 ≥ 16
Minocycline ≧16 ≤ 4 8 ≥ 16
Piperacillin/tazobactam ≧128 ≤ 16/4 32/4-64/4 ≥ 32/4
Trimethoprim/sulfamethoxazole ≧4/76 ≧4/76 ≤ 2/38 - ≥ 4/76
Vancomycin2 ≥ 16 ≤ 2 4-8 ≥ 16
Notes: 1The Clinical and Laboratory Standards Institute (CLSI) minimum inhibitory concentration (MIC) breakpoints for non-Enterobacteriaceae were 
applied for all antimicrobial agents except for vancomycin and flomoxef [Clinical and Laboratory Standards Institute. 2016. M100-S26: performance 
standards for antimicrobial susceptibility testing, 26th informational supplement. CLSI, Wayne, PA.]. 2The CLSI MIC breakpoint for Staphylococcus 
spp. was applied to vancomycin. 3Antimicrobial drug susceptibility test was conducted by using the Epsilometer test (AB Biodisk, Sweden system). 
4Antimicrobial drug susceptibility test was conducted by using the bioMérieux VITEK 2 system (bioMerieux, Hazlewood, MO.). Abbreviation: CLSI: 
Clinical and Laboratory Standards Institute; I: intermediate; MIC: minimal inhibitory concentration; S: susceptible; R: resistant. 
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and vancomycin5. However, the bacteremia caused by 
E. meningoseptica was successfully treated in this case 
with a two-week administration of imipenem-cilastatin 
and ciprofloxacin. In terms of generalization, this case 
description is limited by the restricted number of clinical 
studies in the literature2,3, the lack of minimum inhibitory 
concentration breakpoints of antimicrobial agents to 
E. meningoseptica4, and the paucity of 16S rRNA 
sequencing data due to the inability to perform a reliable 16S 
rRNA sequencing analysis without a valid positive control6.
We suggest a combination therapy as an alternative for 
treatment of multi-drug resistant E. meningoseptica infection 
and undertaking active surveillance of E. meningoseptica 
infections because E. meningoseptica outbreaks could 
subsequently result from exposure to contaminated water 
sources or medical devices.
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